| Literature DB >> 26644304 |
Gustaf Boström1, Mia Conradsson1, Carl Hörnsten1, Erik Rosendahl1,2, Nina Lindelöf1,2, Henrik Holmberg3, Peter Nordström1, Yngve Gustafson1, Håkan Littbrand1,2.
Abstract
OBJECTIVES: The aim of this study is to evaluate the effect of a high-intensity functional exercise program on depressive symptoms among older care facility residents with dementia.Entities:
Keywords: dementia; depression; exercise; frail elderly; randomized controlled trial; residential facilities
Mesh:
Year: 2015 PMID: 26644304 PMCID: PMC5215547 DOI: 10.1002/gps.4401
Source DB: PubMed Journal: Int J Geriatr Psychiatry ISSN: 0885-6230 Impact factor: 3.485
Figure 1Flowchart of the study. Note: ADL, activities of daily living; MMSE, Mini‐Mental State Examination; GDS, 15‐item Geriatric Depression Scale; MADRS, Montgomery–Åsberg Depression Rating Scale.
Baseline characteristics of study participants
| Characteristic | Total ( | Exercise ( | Control ( |
| GDS ≥ 5 ( | GDS < 5 ( |
|
|---|---|---|---|---|---|---|---|
| Age (years) | 85.1 ± 7.1 (65–105) | 84.4 ± 6.2 (67–97) | 85.9 ± 7.8 (65–105) | 0.15 | 84.5 ± 8.2 (65–99) | 85.5 ± 6.5 (67–105) | 0.38 |
| Female sex | 141 (76) | 70 (75) | 71 (76) | 0.86 | 41 (75) | 97 (76) | 0.86 |
| Diagnoses and medical conditions | |||||||
| Dementia type | 0.86 | 0.03 | |||||
| Vascular | 77 (41) | 36 (39) | 41 (44) | 32 (58) | 44 (34) | ||
| Alzheimer | 67 (36) | 34 (37) | 33 (35) | 14 (25) | 51 (40) | ||
| Mixed Alzheimer and vascular | 15 (8) | 8 (9) | 7 (8) | 4 (7) | 11 (9) | ||
| Other | 27 (15) | 14 (16) | 12 (13) | 5 (9) | 22 (17) | ||
| Depressive disorder | 107 (58) | 53 (57) | 54 (58) | 0.88 | 51 (93) | 54 (42) | <0.001 |
| Delirium in the last week | 102 (55) | 48 (52) | 54 (58) | 0.38 | 35 (64) | 66 (52) | 0.13 |
| Previous stroke | 57 (31) | 33 (35) | 24 (26) | 0.15 | 21 (38) | 35 (27) | 0.14 |
| Diabetes mellitus | 29 (16) | 18 (19) | 11 (12) | 0.16 | 11 (20) | 18 (14) | 0.31 |
| Heart failure | 55 (30) | 24 (26) | 31 (33) | 0.26 | 19 (35) | 36 (28) | 0.39 |
| Angina pectoris | 49 (26) | 21 (23) | 28 (30) | 0.24 | 21 (38) | 28 (22) | 0.02 |
| Malignancy, current or in the last 5 years | 20 (11) | 13 (14) | 7 (8) | 0.16 | 8 (15) | 12 (9) | 0.30 |
| Constipation | 121 (65) | 60 (65) | 61 (66) | 0.88 | 43 (78) | 75 (59) | 0.01 |
| Rheumatic disease | 28 (15) | 14 (15) | 14 (15) | 1.00 | 5 (9) | 23 (18) | 0.13 |
| Regular use of drugs | |||||||
| Diuretics | 88 (47) | 41 (44) | 47 (51) | 0.38 | 26 (47) | 62 (48) | 0.89 |
| Analgesics (not ASA) | 112 (60) | 55 (59) | 57 (61) | 0.76 | 36 (65) | 73 (57) | 0.29 |
| Benzodiazepines | 40 (22) | 19 (20) | 21 (23) | 0.72 | 14 (25) | 25 (20) | 0.37 |
| Antidepressants | 102 (55) | 58 (62) | 44 (47) | 0.04 | 31 (56) | 69 (54) | 0.76 |
| Neuroleptics | 31 (17) | 11 (12) | 20 (22) | 0.08 | 13 (24) | 17 (13) | 0.08 |
| Anti‐dementia drugs | 47 (25) | 28 (30) | 19 (20) | 0.13 | 9 (16) | 36 (28) | 0.09 |
| Number of drugs used regularly | 8.3 ± 3.8 (0–22) | 8.4 ± 4.0 (0–22) | 8.2 ± 3.7 (0–20) | 0.75 | 9.1 ± 4.1 (0–21) | 8.0 ± 3.7 (0–22) | 0.07 |
| Assessments | |||||||
| Visual impairment | 26 (14) | 10 (11) | 16 (17) | 0.20 | 8 (15) | 18 (14) | 0.93 |
| Hearing impairment | 32 (17) | 12 (13) | 20 (22) | 0.12 | 13 (24) | 17 (13) | 0.08 |
| Mini‐Mental State Examination (0–30) | 14.9 ± 3.5 (10–26) | 15.4 ± 3.4 (10–23) | 14.4 ± 3.5 (10–26) | 0.06 | 14.9 ± 3.5 (10–26) | 15.0 ± 3.5 (10–25) | 0.99 |
| Mini Nutritional Assessment (0–30) | 21.0 ± 2.7 (12.5–26) | 21.2 ± 2.7 (12.5–26.0) | 20.9 ± 2.6 (14.5–26.0) | 0.35 | 20.2 ± 2.7 (14.5–25.0) | 21.5 ± 2.5 (12.5–26.0) | <0.01 |
| Barthel ADL Index (0–20) | 10.8 ± 4.4 (2–18) | 10.7 ± 4.5 (2–17) | 11.0 ± 4.4 (2–18) | 0.66 | 10.1 ± 4.7 (2–18) | 11.3 ± 4.2 (2–18) | 0.09 |
| Berg Balance Scale (0–56) | 28.9 ± 14.5 (2–54) | 28.6 ± 14.3 (2–52) | 29.3 ± 14.7 (3–54) | 0.71 | 23.0 ± 14.8 (3–49) | 31.6 ± 13.7 (2–54) | <0.001 |
| Neuropsychiatric Inventory (0–144) | 14.8 ± 14.2 (0–82) | 15.2 ± 15.8 (0–82) | 14.4 ± 12.6 (0–42) | 0.68 | 14.3 ± 16.0 (0–82) | 14.7 ± 13.5 (0–58) | 0.84 |
| Pain when walking ( | 35 (20) | 15 (16) ( | 20 (22) | 0.37 | 14 (26) ( | 20 (16) | 0.14 |
| Self‐reported health as good, very good, or excellent | 119 (64) | 60 (65) | 59 (63) | 0.88 | 28 (51) | 90 (70) | 0.02 |
| Outcomes | |||||||
| MADRS (0–60, | 5.7 ± 6.3 (0–31) | 5.6 ± 6.5 (0–31) ( | 5.9 ± 6.1 (0–27) ( | 0.80 | 11.6 ± 7.7 (0–31) | 3.2 ± 3.3 (0–19) | <0.001 |
| GDS (0–15, | 3.8 ± 3.2 (0–13) | 4.0 ± 3.4 (0–13) ( | 3.6 ± 2.9 (0–13) ( | 0.37 | 7.8 ± 2.5 (5–13) | 2.0 ± 1.2 (0–4) | <0.001 |
Note
GDS, 15‐item Geriatric Depression Scale; ASA, acetylsalicylic acid; ADL, activities of daily living; MADRS, Montgomery–Åsberg Depression Rating Scale.
Data are presented as mean ± standard deviation (range) or n (%). For all assessment scales except Neuropsychiatric Inventory, MADRS, and GDS, higher scores indicate higher function. Differences between activity groups and between high and low GDS scores were analyzed using the χ 2 or independent samples t‐test.
Anti‐dementia drugs include acetylcholinesterase inhibitors and memantine.
Within‐group and between‐group differences in GDS and MADRS scores at 4 and 7 months
| Adjusted within‐group | Adjusted between‐group | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Exercise | Control | ||||||||||
| Test |
| Month |
| Mean (95% CI) |
|
| Mean (95% CI) |
| Mean (95% CI) |
| ICC |
| GDS | 183 | 4 | 83 | 0.03 (–0.53, 0.59) | 0.91 | 81 | 0.08 (–0.49, 0.64) | 0.78 | –0.05 (–0.84, 0.75) | 0.91 | 0.032 |
| 184 | 7 | 73 | –0.03 (–0.61, 0.56) | 0.92 | 75 | 0.03 (–0.55, 0.61) | 0.91 | –0.06 (–0.89, 0.76) | 0.88 | ||
| MADRS | 183 | 4 | 83 | 0.40 (–0.77, 1.57) | 0.50 | 80 | 0.33 (–0.85, 1.52) | 0.58 | 0.06 (–1.60, 1.73) | 0.94 | <0.001 |
| 184 | 7 | 73 | –0.08 (–1.30, 1.15) | 0.90 | 74 | –0.24 (–1.47, 0.99) | 0.70 | 0.16 (–1.57, 1.89) | 0.86 | ||
Note
GDS, 15‐item Geriatric Depression Scale; MADRS, Montgomery–Åsberg Depression Rating Scale; CI, confidence interval; ICC, intracluster correlation coefficient.
Performed using linear mixed models with least square means (follow‐up – baseline values), adjusted for age, sex, antidepressant use, cluster, and test‐subject.
Three‐way interactions of activity, time, and subgroup were analyzed in the total sample using linear mixed models adjusting for cluster and test‐subject as random effects and age, sex, and antidepressant use as fixed effects.
Number of participants in analyses with baseline or follow‐up outcome measurement.
Number of participants in subgroup with complete before‐and‐after measurement.
Calculated as the proportion of the total variance attributed to cluster variance in GDS and MADRS scores in the total sample.
Within‐group differences and interaction effects of GDS and MADRS scores in subgroups of participants with high and low levels of depressive symptoms
| Adjusted within‐group | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Test |
| Month | Group | Exercise | Control | Interaction | |||||
|
| Mean (95% CI) |
|
| Mean (95% CI) |
| Mean (95% CI) |
| ||||
| GDS | 183 | 4 | GDS ≥ 5 | 26 | –1.58 (–2.53, –0.63) | 0.001 | 21 | –1.54 (–2.56, –0.50) | 0.004 | –0.09 (–1.76, 1.57) | 0.91 |
| GDS < 5 | 57 | 0.78 (0.14, 1.42) | 0.02 | 60 | 0.72 (0.10, 1.35) | 0.02 | |||||
| 184 | 7 | GDS ≥ 5 | 23 | –1.25 (–2.23, –0.26) | 0.01 | 21 | –1.45 (–2.49, –0.41) | 0.007 | 0.26 (–1.45, 1.98) | 0.76 | |
| GDS < 5 | 50 | 0.53 (–0.14, 1.21) | 0.12 | 53 | 0.59 (–0.06, 1.25) | 0.08 | |||||
| MADRS | 183 | 4 | MADRS ≥ 7 | 27 | –1.69 (–3.66, 0.27) | 0.09 | 23 | –2.80 (–4.90, –0.71) | 0.009 | 1.54 (–1.90, 4.99) | 0.38 |
| MADRS < 7 | 56 | 1.31 (–0.05, 2.67) | 0.06 | 57 | 1.74 (0.40, 3.09) | 0.01 | |||||
| 184 | 7 | MADRS ≥ 7 | 22 | –3.17 (–5.28, –1.06) | 0.003 | 22 | –3.34 (–5.47, –1.21) | 0.002 | –0.08 (–3.67, 3.51) | 0.97 | |
| MADRS < 7 | 51 | 1.32 (–0.08, 2.72) | 0.07 | 51 | 1.07 (–0.33, 2.47) | 0.13 | |||||
Note
GDS, 15‐item Geriatric Depression Scale; MADRS, Montgomery–Åsberg Depression Rating Scale; CI, confidence interval.
Performed using linear mixed models with least square means (follow‐up – baseline values), adjusted for age, sex, antidepressant use, cluster and test‐subject.
Number of participants in analyses with baseline or follow‐up outcome measurement.
Three‐way interactions of activity, time, and subgroup were analyzed in the total sample using linear mixed models adjusted for cluster and test‐subject as random effects and age, sex, and antidepressant use as fixed effects.
Number of participants in subgroup with complete before‐and‐after measurement.
Within‐group differences and interaction effects of GDS and MADRS scores in subgroups of dementia
| Adjusted within‐group | Interaction | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Exercise | Control | ||||||||||
| Group |
| Month | Subgroup |
| Mean (95% CI) |
|
| Mean (95% CI) |
| Mean (95% CI) |
|
| GDS | 183 | 4 | AD | 29 | –0.09 (–1.04, 0.86) | 0.85 | 31 | 0.47 (–0.46, 1.39) | 0.32 | 0.80 (–0.86, 2.46) | 0.34 |
| Non‐AD | 54 | 0.10 (–0.60, 0.79) | 0.79 | 50 | –0.15 (–0.87, 0.57) | 0.68 | |||||
| 184 | 7 | AD | 25 | –0.10 (–1.10, 0.90) | 0.85 | 27 | 0.47 (–0.50, 1.44) | 0.34 | 0.79 (–0.94, 2.53) | 0.37 | |
| Non‐AD | 48 | <0.01 (–0.73, 0.73) | 1.00 | 47 | –0.22 (–0.95, 0.51) | 0.56 | |||||
| MADRS | 183 | 4 | AD | 29 | –0.12 (–2.09, 1.85) | 0.90 | 31 | 1.10 (–0.82, 3.02) | 0.26 | 2.03 (–1.43, 5.49) | 0.25 |
| Non‐AD | 54 | 0.67 (–0.78, 2.12) | 0.37 | 49 | –0.14 (–1.65, 1.37) | 0.85 | |||||
| 184 | 7 | AD | 25 | 1.02 (–1.06, 3.11) | 0.34 | 26 | 0.30 (–1.75, 2.35) | 0.78 | –0.84 (–4.47, 2.78) | 0.65 | |
| Non‐AD | 48 | –0.67 (–2.18, 0.85) | 0.39 | 47 | –0.55 (–2.08, 0.98) | 0.48 | |||||
Note
GDS, 15‐item Geriatric Depression Scale; MADRS, Montgomery–Åsberg Depression Rating Scale; CI, confidence interval; AD, Alzheimer's disease; Non‐AD, non‐Alzheimer dementia.
Performed using linear mixed models with least square means (follow‐up–baseline values), adjusted for age, sex, antidepressant use, cluster and test‐subject.
Number of participants in analyses with baseline or follow‐up outcome measurement.
Three‐way interactions of activity, time, and subgroup were analyzed in the total sample using linear mixed models adjusted for cluster and test‐subject as random effects and age, sex, and antidepressant use as fixed effects.
Number of participants in subgroup with complete before‐and‐after measurement.
Figure 2Adjusted GDS and MADRS scores of participants with high levels of depressive symptoms by activity and follow‐up timepoint. Note: GDS, 15‐item Geriatric Depression Scale; MADRS, Montgomery–Åsberg Depression Rating Scale. P‐values represent comparisons of follow‐up values at 4 and 7 months with baseline values using least square means, adjusted for age, sex, antidepressant use, cluster, and test‐subject. Lower scores represents lower levels of depressive symptoms.